The standard dosage of furmonertinib is oral administration twice daily, 80 mg each time (specific medication use shall follow the doctor's instructions). The daily dosage may be adjusted based on the patient's condition, pharmaceutical dosage form and medical guidance. When calculating the dosage by "pill", it is necessary to consider the dose per single tablet. For example, if each tablet is 40 mg, 2 tablets should be taken each time, with a total of 4 tablets per day; if each tablet is 80 mg, 1 tablet should be taken each time, with a total of 2 tablets per day.
I. Dosage and Administration Frequency Instructions
1. Standard Regimen
The recommended dosage in clinical trials is 80 mg twice daily (at an interval of approximately 12 hours), which can be taken on an empty stomach or with food. For the 40 mg per tablet specification, 2 tablets should be taken per single dose, with a total daily dosage of 4 tablets; for the 80 mg per tablet specification, 1 tablet should be taken per single dose, with a total daily dosage of 2 tablets.
2. Dosage Adjustment Scenarios
Adverse Reaction Management: If severe side effects occur (such as interstitial lung disease, QT interval prolongation), the doctor may recommend suspending medication or reducing the dosage (e.g., adjusting to 40 mg once daily).
Special Populations: Patients with hepatic insufficiency require dosage adjustment based on test results, and the specific regimen must be evaluated by a doctor.
Combination Therapy: The dosage may be adjusted accordingly when used in combination with other anticancer drugs.
II. Precautions for Medication Use
1. Strictly Follow Medical Advice
The medication regimen should be formulated according to pathological type, disease stage, genetic test results (such as EGFR mutation status) and individual differences. Do not increase or decrease the dosage or discontinue the medication without authorization. For instance, some studies suggest that the standard dosage may need to be maintained for specific mutation types (such as T790M-positive).
2. Administration Time and Method
It is recommended to take the medication at a fixed time (e.g., 8 a.m. and 8 p.m.) to avoid missed doses.
If a dose is missed and there are fewer than 6 hours until the next scheduled dose, supplementary administration is not recommended.
Swallow the tablet whole; do not chew or crush it.
3. Monitoring of Adverse Reactions
Common side effects include diarrhea, rash, and oral ulcers; in severe cases, cardiac toxicity or pulmonary inflammation may occur. During medication, regular re-examinations of liver function, electrocardiogram, chest CT, etc., are required. Seek medical attention promptly in case of any abnormalities.
III. Special Instructions
1. Differences in Dosage Forms and Specifications
Pharmaceutical specifications may vary among different manufacturers or regions (e.g., 40 mg per tablet or 80 mg per tablet). Check the dosage indicated in the drug instructions before administration to avoid confusion.
2. Long-term Management
This drug is usually taken for a long time until disease progression or intolerable toxicity occurs. Patients need regular follow-up visits to evaluate therapeutic efficacy and safety, and must not discontinue the medication without authorization due to symptom relief.
Summary
The specific dosage of furmonertinib should be comprehensively determined based on pharmaceutical specifications, medical advice and individual conditions. Patients should confirm the dose per single tablet through the drug instructions, use the drug standardized under the guidance of a doctor, and closely cooperate with follow-up monitoring.
